Theratechnologies Inc. (NASDAQ:THTX – Get Rating) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 83,200 shares, an increase of 22.0% from the May 15th total of 68,200 shares. Based on an average daily volume of 62,600 shares, the short-interest ratio is presently 1.3 days. Approximately 0.1% of the shares of the stock are short sold.
Several hedge funds have recently bought and sold shares of THTX. Range Financial Group LLC bought a new stake in Theratechnologies in the first quarter worth $35,000. Worth Venture Partners LLC grew its stake in shares of Theratechnologies by 11.8% in the 1st quarter. Worth Venture Partners LLC now owns 755,863 shares of the company’s stock worth $1,870,000 after buying an additional 79,900 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Theratechnologies in the 1st quarter worth about $36,000. AIGH Capital Management LLC raised its position in shares of Theratechnologies by 2.8% during the 1st quarter. AIGH Capital Management LLC now owns 2,963,067 shares of the company’s stock valued at $7,335,000 after buying an additional 79,900 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Theratechnologies during the 1st quarter valued at about $34,000. 21.41% of the stock is owned by hedge funds and other institutional investors.
Shares of THTX stock opened at $2.21 on Friday. The company has a current ratio of 2.00, a quick ratio of 1.37 and a debt-to-equity ratio of 5.38. The stock has a market capitalization of $210.22 million, a price-to-earnings ratio of -6.14 and a beta of 1.36. Theratechnologies has a 12-month low of $2.05 and a 12-month high of $4.46. The stock’s 50-day moving average price is $2.51 and its 200-day moving average price is $2.75.
About Theratechnologies (Get Rating)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.
- Get a free copy of the StockNews.com research report on Theratechnologies (THTX)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.